Cell signaling

Cell Signaling Technology Named a Top Charitable Company in Massachusetts by the Boston Business Journal

Retrieved on: 
Thursday, September 24, 2020

CST ranked 71st in Massachusetts among top charitable companies, with a total contribution of $470,000 to MA local charities.

Key Points: 
  • CST ranked 71st in Massachusetts among top charitable companies, with a total contribution of $470,000 to MA local charities.
  • "We are flattered to be recognized by the Boston Business Journal for our contributions within the Commonwealth of Massachusetts."
  • Cell Signaling Technology (CST) is a private, family-owned company, founded by scientists and dedicated to providing high quality research tools to the biomedical research community.
  • Cell Signaling Technology and CST are trademarks of Cell Signaling Technology, Inc.
    View original content to download multimedia: http://www.prnewswire.com/news-releases/cell-signaling-technology-named-...

Cell Signaling Technology Named a Top Charitable Company in Massachusetts by the Boston Business Journal

Retrieved on: 
Thursday, September 24, 2020

DANVERS, Massachusetts, Sept. 24, 2020 /PRNewswire/ -- Cell Signaling Technology, Inc. (CST), a discovery technology company and leading provider of antibodies, kits, and services, was named by the Boston Business Journal (BBJ) for the 5th year in a row, as a 2020 top corporate charitable contributor in Massachusetts, at the Annual Corporate Citizenship Awards on September 10th in Boston.

Key Points: 
  • DANVERS, Massachusetts, Sept. 24, 2020 /PRNewswire/ -- Cell Signaling Technology, Inc. (CST), a discovery technology company and leading provider of antibodies, kits, and services, was named by the Boston Business Journal (BBJ) for the 5th year in a row, as a 2020 top corporate charitable contributor in Massachusetts, at the Annual Corporate Citizenship Awards on September 10th in Boston.
  • "We are flattered to be recognized by the Boston Business Journal for our contributions within the Commonwealth of Massachusetts."
  • Cell Signaling Technology (CST) is a private, family-owned company, founded by scientists and dedicated to providing high quality research tools to the biomedical research community.
  • Cell Signaling Technology and CST are trademarks of Cell Signaling Technology, Inc.

Achieve Life Sciences Announces Results from Evaluation of Cytisinicline (cytisine) versus Chantix® (varenicline) in 5-HT3 Receptor Binding Assay Study

Retrieved on: 
Friday, September 18, 2020

Using a radioligand antagonist displacement design, the study reported an IC50 of 0.50 mM for cytisinicline and 0.25 M for varenicline, representing a 2000-greater fold agonist binding affinity to the 5-HT3 receptor for varenicline compared to cytisinicline.

Key Points: 
  • Using a radioligand antagonist displacement design, the study reported an IC50 of 0.50 mM for cytisinicline and 0.25 M for varenicline, representing a 2000-greater fold agonist binding affinity to the 5-HT3 receptor for varenicline compared to cytisinicline.
  • "It is well-established that agonist activation of 5-HT3 receptors in the brain stem directly leads to nausea and vomiting.
  • Achieve's focus is to address the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline.
  • Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor.

AlloVir Announces the FDA Clearance of Investigational New Drug Application (IND) for ALVR109 for the Treatment of High-Risk COVID-19 Patients

Retrieved on: 
Thursday, September 17, 2020

SARS-CoV-2 continues to have a devastating impact on patients and families around the world,said David Hallal, Chairman and Chief Executive Officer of AlloVir.

Key Points: 
  • SARS-CoV-2 continues to have a devastating impact on patients and families around the world,said David Hallal, Chairman and Chief Executive Officer of AlloVir.
  • There is an increasing body of evidence about the important role of T cells in the bodys fight against COVID-19.
  • Early research suggests that T cells play an important role in the bodys fight against COVID-19.
  • Over 80% of hospitalized patients with COVID-19 are lymphopenic, with reduced CD8+ and CD4+ T cell counts.

Keros Therapeutics Presents Results from Preclinical Studies Investigating KER-012 at the American Society for Bone and Mineral Research 2020 Annual Meeting

Retrieved on: 
Friday, September 11, 2020

KER-012 is a modified activin receptor type II ligand trap designed to bind to and inhibit activins and SMAD 2/3 signaling.

Key Points: 
  • KER-012 is a modified activin receptor type II ligand trap designed to bind to and inhibit activins and SMAD 2/3 signaling.
  • Words such as "anticipates," "believes," "expects," "intends," plans, potential, "projects, would and "future" or similar expressions are intended to identify forward-looking statements.
  • Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.
  • All forward-looking statements contained in this press release speak only as of the date on which they were made.

DiaSorin and MeMed partner to develop and commercialize novel host immune response based diagnostics solution

Retrieved on: 
Tuesday, September 8, 2020

Licensing Agreement to add MeMed BV, Immune System Based Protein Signature Test for Distinguishing between Bacterial vs.

Key Points: 
  • Licensing Agreement to add MeMed BV, Immune System Based Protein Signature Test for Distinguishing between Bacterial vs.
  • A pioneer in the field of host immune response, MeMed developed MeMed BV, a technology that integrates machine learning with measurements of three key host-immune proteins: tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), interferon gamma induced protein-10 (IP-10), and C-reactive protein (CRP).
  • The MeMed solution enables physicians to differentiate accurately between bacterial and viral infections, thus supporting fast and better-informed treatment and patient management decisions.
  • "Im really proud that DiaSorin is the first company to partner with MeMed for the scale-up of this novel test.

DiaSorin and MeMed partner to develop and commercialize novel host immune response based diagnostics solution

Retrieved on: 
Tuesday, September 8, 2020

Licensing Agreement to add MeMed BV, Immune System Based Protein Signature Test for Distinguishing between Bacterial vs.

Key Points: 
  • Licensing Agreement to add MeMed BV, Immune System Based Protein Signature Test for Distinguishing between Bacterial vs.
  • A pioneer in the field of host immune response, MeMed developed MeMed BV, a technology that integrates machine learning with measurements of three key host-immune proteins: tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), interferon gamma induced protein-10 (IP-10), and C-reactive protein (CRP).
  • The MeMed solution enables physicians to differentiate accurately between bacterial and viral infections, thus supporting fast and better-informed treatment and patient management decisions.
  • "Im really proud that DiaSorin is the first company to partner with MeMed for the scale-up of this novel test.

DiaSorin and MeMed partner to develop and commercialize novel host immune response based diagnostics solution

Retrieved on: 
Tuesday, September 8, 2020

Licensing Agreement to add MeMed BV, Immune System Based Protein Signature Test for Distinguishing between Bacterial vs.

Key Points: 
  • Licensing Agreement to add MeMed BV, Immune System Based Protein Signature Test for Distinguishing between Bacterial vs.
  • A pioneer in the field of host immune response, MeMed developed MeMed BV, a technology that integrates machine learning with measurements of three key host-immune proteins: tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), interferon gamma induced protein-10 (IP-10), and C-reactive protein (CRP).
  • The MeMed solution enables physicians to differentiate accurately between bacterial and viral infections, thus supporting fast and better-informed treatment and patient management decisions.
  • "Im really proud that DiaSorin is the first company to partner with MeMed for the scale-up of this novel test.

Astex Pharmaceuticals Announces That Tolinapant (ASTX660), a Novel Antagonist of Cellular and X-linked Inhibitors of Apoptosis Proteins, Has Been Granted Orphan Drug Designation for the Treatment of T-cell Lymphomas by the US FDA

Retrieved on: 
Monday, August 31, 2020

Orphan drug designation is granted to drugs intended to treat a rare disease or condition.

Key Points: 
  • Orphan drug designation is granted to drugs intended to treat a rare disease or condition.
  • The designation provides for seven years of marketing exclusivity in the US following product approval, as well as certain tax incentives and grants.
  • Astexs development of tolinapant is aimed at bringing a new therapeutic option for patients with this type of cancer.
  • Tolinapant is a novel, orally administered, non-peptidomimetic antagonist of the cellular and X-linked inhibitors of apoptosis proteins (cIAP1/2 and XIAP).

Global Apoptosis Assays Industry (2020 to 2026) - Products, Detection Technologies, Applications and End-use Markets - ResearchAndMarkets.com

Retrieved on: 
Friday, August 28, 2020

The "Global Apoptosis Assays Market - Products, Detection Technologies, Applications and End-Use Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Apoptosis Assays Market - Products, Detection Technologies, Applications and End-Use Markets" report has been added to ResearchAndMarkets.com's offering.
  • Drug Discovery & Development is the principal application for Apoptosis Assays, which, however, is anticipated to maintain the slowest CAGR over the analysis period.
  • While COVID-19 may not have an adverse impact on the market for Apoptosis Assays as anticipated, there is a definite slowdown in demand, which has to be addressed with requisite measures.
  • The overall Apoptosis Assays market, globally, expected to touch US$4.5 billion in 2020.